Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Midazolam for IONV in C-Section
NCT05736341Completed
- Sponsor
- Yonsei University
- Start
- May 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of remimazolam in intraoperative nausea and vomiting (IONV) (2 arms), sponsored by Yonsei University. Primary endpoint: Intraoperative Nausea and Vomiting. Started May 2023; status: completed.
02
Drugs
remimazolam
03
Conditions
intraoperative nausea and vomiting (IONV)
Beyond the preview
Go deeper on NCT05736341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736341.